TOP 5 MOST VIEWED ARTICLES
RECENT COMMENTS
Article type: Editorial
Keywords: geriatric oncology, International Society of Geriatric Oncology, .
This article has 0 comments
Elderly patients deserve better
Two sets of statistics have recently been published which together have major implications for Europe’s cancer patients of the future. In February the International Agency for Research on Cancer revealed that the number of new cases in Europe rose by 10% between 2004 and 2006, from 2.9 million to 3.2 million. In March, a report published in the Annals of Oncology estimated that the rate of cancer mortality in Europe fell by 12.5% between 1987 and 2002, from 191 to 167 per 100,000 head of population
» Kathy Redmond
To read the complete article please click on the pdf icon
COMMENTS (0)
When submitted, your comment will be moderated. Messages which may be considered defamatory, which incite hatred or contain foul or abusive language, or are gratuitously offensive, will not be published. Please ensure that your comments are concise and relevant to the topic in question. Off-topic comments and comments without a username will not be published.
ESO reserves the absolute right not to publish comments.
ESO reserves the absolute right not to publish comments.
CancerWorld invites you to visit:
European School of Oncology -
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
Euro-Arab School of Oncology - is a joint initiative between the Egyptian Ministry of Health and Population and ESO. EASO intends to enhance and support education in the oncology field in all the Arab countries.
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, AstraZeneca, Eisai, Eli Lilly, GlaxoSmithKline, Merck and Novartis.






